Variation in care in pediatric crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 49, Issue 3, 2009, Pages 297-303

  Colletti, Richard B ^a   Baldassano, Robert N ^b   Milov, David E ^c   Margolis, Peter A ^d   Bousvaros, Athos ^e   Crandall, Wallace V ^f   Crissinger, Karen D ^g   D'Amico, Michael A ^a   Day, Andrew S ^h   Denson, Lee A ^d   Dubinsky, Marla ⁱ   Ebach, Dawn R ^j   Hoffenberg, Edward J ^k   Kader, Howard A ^l   Keljo, David J ^m   Leibowitz, Ian H ⁿ   Mamula, Petar ^b   Pfefferkorn, Marian D ^o   Qureshi, M Azim ^p  

^a UNIVERSITY OF VERMONT   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NEMOURS CHILDREN S HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF SOUTH ALABAMA   (United States)

^h SYDNEY CHILDREN'S HOSPITAL   (Australia)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l SINAI HOSPITAL OF BALTIMORE   (United States)

^m CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁿ INOVA   (United States)

^o RILEY HOSPITAL FOR CHILDREN   (United States)

^p PENN STATE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Crohn disease Inflammatory bowel; Disease Quality; Improvement Variation in care

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ARTICLE; CHILD; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; GASTROENTEROLOGY; HUMANS; MALE; METHYLTRANSFERASES; QUALITY OF HEALTH CARE; THINNESS; TUBERCULOSIS;

EID: 70349087382     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181919695     Document Type: Article

References (31)

1. Berwick DM, Nolan TW. Physicians as leaders in improving health care. Ann Intern Med 1998;128:289-292
2. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348:2635-2645
3. Jha AK, Li Z, Orav EJ, et al. Care in U.S. hospitals-the Hospital Quality Alliance Program. N Engl J Med 2005; 353:265-274
4. Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. N Engl J Med 2007;357:1515-1523
5. http://www.cmwf.org/publications/publications-show.htm?doc-id= 401577&#doc401577.
6. Wolters FL, Russel MGVM, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483-496
7. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroen-terol Hepatol 2007;5:597-601.
8. Chassin MR, Galvin RW. the National Roundtable on Health Care QualityThe urgent need to improve health care quality. JAMA 1998;280:1000-1005
9. Berwick DM. Controlling variation in health care. Med Care 1991;29:1212-1225
10. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the Twenty-first Century. Washington, DC: National Academy Press; 2001.
11. Schechter MS, Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 2005;147:295-301.
12. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514.
13. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classi-fication of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753
14. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-9.
15. IBD Guideline Team, Cincinnati Children's Hospital Medical Center: evidence-based care guideline for management of pediatric moderate/severe inflammatory bowel disease (IBD), http://www. cincinnatichildrens.org/svc/alpha/ h/health-policy/ev-based/ibd.htm, Guideline 29, April 5, 2007:1-29.
16. Clark M, Colombel JF, Feagan BC, et al. American Gastro-enterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39.
17. Panaccione R, Fedorak RN, Aumais G, et al. Canadian Association of Gastroenterology clinical practice guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol 2004;18:503-8. 18.
18. IBD Working Group of the European Society for Pediatric Gastro-enterology, Hepatology and Nutrition (ESPGHAN). Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41:1-7.
19. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-1689
20. Bousvaros A, Antonioli D, Colletti R, et al. Differentiating ulcerative colitis from Crohn's disease in children and young adults: a report of a working group of the North American Society of Pediatric Gastroenterology Hepatology and Nutrition, and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653-674
21. Walfish A, Sachar D. Phenotype classification in IBD: is there an impact on therapy? Inflamm Bowel Dis 2007;13:1573-5.
22. Package insert for azathioprine/6-mercaptopurine. Imuran1, Prometheus Laboratories, Inc., San Diego, California; 2005.
23. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thio-purine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:593-9.
24. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100:2239-2247
25. Clinical Policy Bulletin: Inflammatory Bowel Disease. http:// www.aetna.com/cpb/medical/data/200-299/0249.html. Accessed February 18, 2008.
26. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000: CD000067.
27. Colletti RB. Next steps on the TPMT 6-TGN pathway. J Pediatr Gastroenterol Nutr 2006;43:282-283
28. Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis 2007;13:890-895
29. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflam-matory bowel disease receiving optimal care? Am J Gastroenterol 2005;100:1357-1361
30. Tsai AC, Morton SC, Mangione CM, et al. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care 2005;11:478-488
31. Tremaine WJ, Sandborn WJ, Loftus EV, et al. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001;96:2401-2406